Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses

NEW YORK--(BUSINESS WIRE)--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ: CERE) and AbbVie, Inc. (“AbbVie”) (NYSE: ABBV). Investors who purchased Cerevel and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/cere.

Investigation Details:

The investigation concerns whether Cervel’s board of directors breached its fiduciary duties and failed to provide relevant information to its shareholders before the merger.

On December 6, 2023, Cerevel announced that it would be acquired by AbbVie and that the transaction is expected to close in the middle of 2024. Under the merger terms, AbbVie will acquire all outstanding Cerevel shares for $45.00 per share in cash. The transaction values Cerevel at a total equity value of approximately $8.7 billion.

What’s Next?

If you are aware of any facts relating to this investigation or purchased Cerevel shares, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.